Leukemia, a devastating hematological malignancy, has long been a formidable challenge in the realm of oncology. At Alfa Cytology, we have dedicated to unraveling the complexities of this disease, driven by a relentless pursuit of innovative solutions.
Introduction to Leukemia
Leukemia is a type of cancer that originates in the haematopoietic tissues (mainly the bone marrow and lymphatic system).
Fig.1 Cytology of leukemia.
Leukemia is broadly classified into four main types:
- Acute Lymphoblastic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)
- Chronic Lymphocytic Leukemia (CLL)
- Chronic Myeloid Leukemia (CML)
Pathogenesis of Leukemia
One of the hallmarks of leukemia is the accumulation of genetic mutations, which can disrupt the normal regulation of cell growth, proliferation, and survival.
Fig.2 NF-κB pathway mutations in chronic lymphocytic leukaemia. (Fabbri, G., & Dalla-Favera, R., 2016)
Therapy Development for Leukemia
Promising leukemia pipeline therapies in various stages of development include:
| Drugs |
Company |
Phase |
MoA |
RoA |
| Omidubicel |
Gamida Cell |
Registered |
Cell replacements |
Intravenous |
| Uproleselan |
GlycoMimetics |
Phase III |
E-selectin inhibitors |
Intravenous |
| Pevonedistat |
Takeda Oncology |
Phase III |
NEDD 8 activating enzyme inhibitors |
Intravenous |
| SKLB1028 |
CSPC Ouyi Pharmaceutical |
Phase III |
Bcr-abl tyrosine kinase inhibitors; Epidermal growth factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Lyn protein-tyrosine kinase inhibitors |
Oral |
| BPX-501 |
Bellicum Pharmaceuticals |
Phase II |
Immunologic cytotoxicity; T lymphocyte replacements |
Intravenous |
| ALT 803 |
ImmunityBio |
Phase II |
Interleukin-15 receptor agonists |
Intravenous |
Our Services
At Alfa Cytology, with a team of highly skilled and experienced biological experts who have worked in the industry for many years, our company understands the unique challenges associated with leukemia therapy and is committed to providing cutting-edge solutions. We have developed a profound understanding of the molecular mechanisms of leukemia and have conducted extensive research in this field.
Therapeutics Development Services
Diagnostic Development Services
Preclinical Research Services
Preclinical animal models play a crucial role in the development of novel leukemia therapies. We offer a specialized service for the development and characterization of advanced leukemia animal models.
| Acute Lymphoblastic Leukemia (ALL) Animal Model |
- Induced by the fusion genes such as ETV6/RUNX1 (TEL/AML1) and ETV6.
|
| Acute Myeloid Leukemia (AML) Animal Model |
- Expressing human acute myeloid leukemia-inducing gene in mice bone marrow cells utilizing retrovirus.
- Transgenic AML models expressing CBF β-SMMHC gene in mice.
- Collaborative induction with multiple oncogenes (i.e. PML-RAPα fusion oncogene, Ras oncogene).
- Acceleration of AML development with a chemical mutagen.
- Deletion of a tumor suppressor gene such as P53, RB, INK4a, ARF, APC, PTCH, SAMAD4/DPC4, PTEN, TSC1/2, NF1, WT1, MSH2, MLH1, ATM, NBS1, CHK2, BRCA1/2, FA, and VHL.
|
| Chronic Lymphoblastic Leukemia (CLL) Animal Model |
- Generation of TCL1 transgenic mice.
|
| Chronic Myeloid Leukemia (CML) Animal Model |
- Induced by BCR-ABL oncogene.
- Induced by the fusion genes such as TEL/PDGβR, TEL/ABL, TEL/ JAK2 and H4/PDGβR.
|
For more information about our leukemia research and development initiatives, or to inquire about our comprehensive services, please don't hesitate to contact us at Alfa Cytology. Our dedicated team of experts is committed to collaborating with healthcare providers and research institutions to drive progress in the fight against leukemia.
Reference
- Fabbri, G., & Dalla-Favera, R. (2016). The molecular pathogenesis of chronic lymphocytic leukaemia. Nature Reviews Cancer, 16(3), 145-162.
! For research use only.
Related Services
